New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
Is There a Safe and Effective Anticoagulation Strategy for Secondary Prevention of Non-Cardioembolic Ischemic Stroke?
Non-Statin Cholesterol Management Update
LIVE UPDATE FROM ACC25: More Support for the “Factor XI Hypothesis”
MANAGEMENT OF PSVT: UPDATE FROM ACC25
LIVE UPDATE FROM AHA24: What do we know about antiplatelets added to anticoagulation in patients with AF?
Update on Emerging Anticoagulants
IgAN Update Fall 2024
Update From ESC24: New Data on Non-Statin Lipid Lowering Therapies and Reduced CV Risk
Optimal Contemporary Management of Hypertrophic Cardiomyopathy: The Importance of Early Diagnosis and Targeted Therapy
Early, Optimal Management of CKD and Cardiorenal Disease to Prevent Disease Progression and Improve Outcomes
Human Nephrogenesis in Preterm Infants
Albuminuria: The Canary in the Coal Mine of Kidney and Cardiorenal Disease
Long-Term Response to Rituximab vs Tacrolimus in Children with Steroid-Dependent Nephrotic Syndrome
The Conundrum of Alkali Therapy in Calcium Phosphate Stone Formers
Live Tweetorial from ISC24: Predictors of Hematoma Expansion and Response to Andexanet in ANNEXa-I
Barriers to Care in Achieving Early Rhythm Control in Atrial Fibrillation
ATTR-PN: A Primer
Journal Club: Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage